The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
UroGen Pharma Ltd (URGN)

UroGen Pharma is a biotechnology company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co. has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Co.'s Jelmyto® (mitomycin) for pyelocalyceal solution, and its UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively.

URGN SEC Filing Email Alerts Service

Company Name:  UroGen Pharma Ltd
Website:  www.urogen.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding URGN:  16
Total Market Value Held by ETFs:  $18.40M
Total Market Capitalization:  $518.00M
% of Market Cap. Held by ETFs:  3.55%
March 29, 2024    1:54 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree URGN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.60 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)

Analysts' Target Price:
URGN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

UroGen Pharma Ltd (URGN) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.